Related Experiment Video
Updated: Apr 28, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Clinical biomarkers in colorectal cancer
1University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Colorectal cancer remains the second leading cause of cancer-related death in the United States. While chemo- therapy remains the backbone upon which treatment for meta- static colorectal cancer is built, targeted therapies have been employed, albeit with mixed results, in the management of this disease. Nonetheless, increased understanding in recent years of the complexity and heterogeneity of cellular abnormalities driving these tumors has identified potential targets for future interven- tions. This article will review the seminal biomarkers of predic- tive and prognostic importance currently used in the treatment of patients with colorectal cancer, and will highlight additional promising biomarkers which may be incorporated into clinical practice in the future.
Insights
Colorectal cancer treatment relies on chemotherapy and targeted therapies. Understanding tumor biomarkers is key for improving patient outcomes and developing new interventions for this deadly disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancer is a leading cause of cancer death in the US.
- Chemotherapy is the primary treatment for metastatic colorectal cancer.
- Targeted therapies show mixed results but offer potential.
Purpose of the Study:
- Review current predictive and prognostic biomarkers for colorectal cancer.
- Highlight emerging biomarkers for future clinical application.
- Discuss the role of biomarkers in personalized colorectal cancer treatment.
Main Methods:
- Literature review of seminal and emerging biomarkers.
- Analysis of biomarker relevance in colorectal cancer treatment.
- Synthesis of current and future biomarker applications.
Main Results:
- Established biomarkers are crucial for guiding colorectal cancer therapy.
- Tumor heterogeneity necessitates identification of novel biomarkers.
- Biomarker discovery enhances targeted treatment strategies.
Conclusions:
- Biomarkers are essential for optimizing colorectal cancer patient care.
- Continued research into novel biomarkers will improve treatment efficacy.
- Personalized medicine approaches driven by biomarkers are the future of colorectal cancer management.
